Mpox in Pregnancy: High Risk of Fetal Loss and Congenital Infection
Infection with the MPXV clade I virus during pregnancy carries a significant risk of fetal loss and congenital infection,notably during the first trimester. This finding underscores the urgent need for targeted preventive measures and clinical strategies to protect both pregnant women and thier infants in areas where mpox is endemic or experiencing outbreaks.
Recent data highlights the vulnerability of pregnant individuals to severe outcomes from mpox. The first trimester appears to be a period of heightened risk, possibly due to the developing immune system of the fetus and the impact of maternal immune responses on fetal advancement. Congenital infection, where the virus is transmitted from mother to child, can lead to a range of complications, including stillbirth, developmental abnormalities, and illness in the newborn.
The World Health Institution (WHO) declared mpox a Public Health Emergency of International Concern in 2022, drawing global attention to the escalating outbreak. WHO Declaration While the global emergency status has been lifted as of May 2023, WHO Update mpox continues to circulate, and cases are still reported in various regions. This ongoing presence necessitates continued vigilance, especially for vulnerable populations like pregnant women.
Currently, there are no specific mpox vaccines specifically studied for use in pregnancy. CDC FAQ on Mpox Vaccine Though, the Centers for Disease Control and Prevention (CDC) provides guidance on vaccination for pregnant or breastfeeding individuals based on individual risk assessment. Preventive strategies focus on avoiding exposure to the virus through practices like safe sex, avoiding close contact with infected individuals, and practicing good hygiene.
Clinical management of mpox in pregnant women requires a multidisciplinary approach. Healthcare providers should consider the potential risks to both mother and fetus when making treatment decisions. Antiviral medications,such as tecovirimat (TPOXX),might potentially be considered,but their safety and efficacy in pregnancy are still being evaluated. CDC on Mpox Treatment Close monitoring of the mother and fetus is crucial throughout the course of the illness.
Further research is essential to better understand the impact of MPXV clade I infection on pregnancy outcomes and to develop effective preventive and therapeutic strategies. Studies are needed to evaluate the safety and efficacy of vaccines and antiviral medications in pregnant women, as well as to identify biomarkers that can predict the risk of fetal loss and congenital infection.
